Presentation is loading. Please wait.

Presentation is loading. Please wait.

MRSA Prescreening and Eradication: New England Baptist Hospital Experience David H. Kim, MD Director of Medical Education New England Baptist Hospital.

Similar presentations


Presentation on theme: "MRSA Prescreening and Eradication: New England Baptist Hospital Experience David H. Kim, MD Director of Medical Education New England Baptist Hospital."— Presentation transcript:

1 MRSA Prescreening and Eradication: New England Baptist Hospital Experience David H. Kim, MD Director of Medical Education New England Baptist Hospital Boston, MA

2 New England Baptist Hospital 150-bed adult medical/surgical hospital located in Mission Hill area of Boston Orthopaedic subspecialty hospital & “Center of Excellence” –Acute inpatient discharges: 75% Orthopedic 8% General Surgery 17% Medical Orthopaedic Surgery ~ 10,000/cases a year

3 Total Inpatient Volume Massachusetts Market Orthopaedic Surgery

4 New England Baptist Hospital Market Growth ~ 11%

5 Methicillin-resistant Staphylococcus Aureus

6 S. Aureus Most important pathogen in SSI Most important pathogen in SSI Most SSI caused by strains carried by patient into hospital Most SSI caused by strains carried by patient into hospital Anterior nares main niche Anterior nares main niche Nasal carriage of S. aureus is risk factor for SSI [Kluytmans et al, Clin Microbiol Rev 1997] Nasal carriage of S. aureus is risk factor for SSI [Kluytmans et al, Clin Microbiol Rev 1997]

7 MRSA vs. MSSA Infection associated with higher mortality [Melzer et al, Clin Infect Dis 2003] Infection associated with higher mortality [Melzer et al, Clin Infect Dis 2003] Survive in dry conditions & on inanimate surfaces up to 20 days [Clarke et al, Ir Med J 2001] Survive in dry conditions & on inanimate surfaces up to 20 days [Clarke et al, Ir Med J 2001] Prevalence increasing Prevalence increasing

8 History of MRSA Resistance to PCN within 1 yr Resistance to PCN within 1 yr –By 1950’s, 3/4 of S. aureus strains PCN-resistant –Today, 90-95% clinical strains PCN-resistant 1959—methicillin (1 st antistaph PCN) introduced 1959—methicillin (1 st antistaph PCN) introduced –1 st MRSA strain within 2yrs –60% of clinical S. aureus strains isolated from ICU’s are MRSA

9 Linezolid Introduced in 2000 for MRSA Introduced in 2000 for MRSA –Resistant strain reported within 1 year [Tsiodras et al, Lancet 2001]

10 Daptomycin Introduced in 2003 for MRSA Resistant strain reported within 2 years Resistant strain reported within 2 years [Mangili et al, Clin Infect Dis 2005]

11 Vancomycin Resistance Recognized after almost 40 yrs Recognized after almost 40 yrs –1 st glycopeptide-intermediate S. aureus (GISA) isolated in Japan in 1996 –1 st glycopeptide-intermediate S. aureus (GISA) isolated in Japan in 1996 [Hiramatsu et al, J Antimicrob Chemother 1997] High level resistance appeared in Detroit in 2002 High level resistance appeared in Detroit in 2002 –vanA gene complex acquired from VRE [Centers for Disease Control and Prevention, MMWR Morb Mortal Wkly Rep 2002] 2 nd strain in Philadelphia 2 nd strain in Philadelphia 3 rd strain in New York 3 rd strain in New York

12 MIC Creep Increases in vancomycin MIC in both MRSA & MSSA over time [Rhee et al, Clin Infect Dis 2005] Increases in vancomycin MIC in both MRSA & MSSA over time [Rhee et al, Clin Infect Dis 2005] Largest study of >6000 S. aureus isolates over 5 yrs in California university hospital Largest study of >6000 S. aureus isolates over 5 yrs in California university hospital –Drift towards reduced susceptibility –  ing percentage of isolates with MIC ≥ 1.0 μg/mL 19.9% in % in % in 2004 [Wang et al, J Clin Microbiol 2006] 70.4% in 2004 [Wang et al, J Clin Microbiol 2006]

13 MIC Creep  ’d vancomycin failure rate in MRSA infections in setting of  ’d MICs  ’d vancomycin failure rate in MRSA infections in setting of  ’d MICs –[Sakoulas et al, J Clin Microbiol 2005]

14 Surgical Site Infection (SSI) Increased costs Increased costs –Median hospital stay increased 2 wks –Rehospitalization rates doubled –Overall costs tripled [Whitehouse et al, Infect Control Hosp Epidemiol 2002]

15 SSI Costs Capitation Capitation –DRGs do not cover cost of treating nosocomial infection (considered “preventable”)

16 Risk of SSI Increased in Nasal Carriers Nasal carriage only independent risk factor for S. aureus SSI in orthopaedic implant surgery Nasal carriage only independent risk factor for S. aureus SSI in orthopaedic implant surgery –Kalmeijer et al, Infect Control Hosp Epidemiol 2000 SSI rate 2-9x higher in carriers SSI rate 2-9x higher in carriers –Kluytmans et al, Clin Microbiol Rev 1997 –Perl et al, Ann Pharmacother 1998 –Wenzel et al, J Hosp Infect 1995 In S. aureus SSI, S.aureus isolates from wound match nares 85% of time In S. aureus SSI, S.aureus isolates from wound match nares 85% of time –Perl et al, N Engl J Med 2002

17 Risk Factors for S. Aureus SSI Observational study of 357 cardiac surgery patients Observational study of 357 cardiac surgery patients 27% nasal carriers 27% nasal carriers SSI rate 6.4% SSI rate 6.4% –S. aureus in 64% –8/16 infections in nasal carriers Independent risk factors Independent risk factors –Diabetes (RR 5.9) –Reoperation (RR 3.1) –S. aureus nasal carriage (RR 3.1) [Munoz et al, J Hosp Infect 2008]

18 Risk of MRSA Nasal Carriage Case-control study of 308 vascular surgery pts (nasal swabs) Case-control study of 308 vascular surgery pts (nasal swabs) –11.4% MSSA carriers –4.2% MRSA carriers 2.9% on admission 2.9% on admission 1.3% acquired in hospital 1.3% acquired in hospital Transfer from another dept or facility risk factors for MRSA carriage Transfer from another dept or facility risk factors for MRSA carriage MRSA infection rate MRSA infection rate –30.8% in MRSA carriers –0.68% in noncarriers [Morange-Saussier et al, Ann Vasc Surg 2006]

19 Environmental Reservoirs MRSA infected/colonized pts contaminate rooms, contribute to endemic MRSA MRSA infected/colonized pts contaminate rooms, contribute to endemic MRSA Prospective study of 25 MRSA pts Prospective study of 25 MRSA pts Sampling of isolation rooms Sampling of isolation rooms –53.6% of surface samples positive –28% of air samples –40.6% of settle plates Isolates identical or closely related in 70% of patients Isolates identical or closely related in 70% of patients [Sexton et al, J Hosp Infect 2006]

20 Environmental Reservoirs [Sexton et al, J Hosp Infect 2006]

21 Potential Airborne Transmission [Sexton et al, J Hosp Infect 2006]

22 Airborne Transmission MRSA counts remain elevated for up to 15 minutes after bed making MRSA counts remain elevated for up to 15 minutes after bed making Consider air ventilation & filtration Consider air ventilation & filtration Keep doors closed Keep doors closed [Shiomori et al, J Hosp Infect 2002]

23 Inadequate Patient Space 18-month prospective study 18-month prospective study Addition of fifth bed to four-bed bay Addition of fifth bed to four-bed bay  ’d relative risk of MRSA colonization 315%  ’d relative risk of MRSA colonization 315% [Kibbler et al, J Hosp Infect 1998]

24 Long-term Care Facilities 44% of environmental surfaces tested positive for MRSA 44% of environmental surfaces tested positive for MRSA [Asoh et al, Intern Med 2005]

25 Decolonization of Carriers Intranasal mupirocin (Bactroban) Intranasal mupirocin (Bactroban) Eradicates nasal colonization in most patients Eradicates nasal colonization in most patients Reduces S. aureus infections Reduces S. aureus infections –Herwaldt, J Hosp Infect 1998; Kluytmans et al, Infect Control Hosp Epidemiol 1996; Tacconelli et al, Clin Infect Dis 2003 (dialysis) –Cimochowski et al, Ann Thorac Surg 2001; Kluytmans et al, Infect Control Hosp Epidemiol 1996 (Cardiovasc) –Gernaat-van der Sluis et al, Acta Orthop Scand 1998 (ortho) –Perl et al, N Engl J Med 2002 (mixed)

26 Mupirocin and the Risk of S. Aureus (MARS) Study University of Iowa University of Iowa Prospective randomized double-blind placebo- controlled Prospective randomized double-blind placebo- controlled 4020 enrolled, 3864 analyzed 4020 enrolled, 3864 analyzed –Elective cardiothoracic, general, oncologic, gyn, neuro surgery Rate of S. aureus SSI (primary endpoint) Rate of S. aureus SSI (primary endpoint) –2.3% in mupirocin pts –2.4% in placebo pts No reduction in rate of S. aureus SSI No reduction in rate of S. aureus SSI –Among nasal carriers, risk of nosocomial S. aureus infection decreased by half (7.7% to 4.0%) [Perl et al, N Engl J Med 2002]

27 MARS Study Mupirocin nasal swab for up to 5 days Mupirocin nasal swab for up to 5 days Chlorhexidine shower for cardiothoracic pts night before & morning of surgery Chlorhexidine shower for cardiothoracic pts night before & morning of surgery Power analysis Power analysis –4046 pts to detect 50%  in S. aureus SSI (estimated reduction of 2.8% (57 pts) to 1.4% (28 pts) with 85% power 4030 enrolled, 3551 completed study 4030 enrolled, 3551 completed study –82.6% received at least 3 mupirocin doses [Perl et al, N Engl J Med 2002]

28 MARS Study Infection Rates MARS Study Infection Rates Risk of S. aureus infection among nasal carriers cut in half Risk of S. aureus infection among nasal carriers cut in half S. aureus SSI 4.5x higher in carriers receiving placebo S. aureus SSI 4.5x higher in carriers receiving placebo 84.6% isolates from SSI pts identical between wound & nares 84.6% isolates from SSI pts identical between wound & nares 39 different strains among 77 patients 39 different strains among 77 patients Mupirocin resistance in 6/1021 (0.6%) isolates over 4 yrs Mupirocin resistance in 6/1021 (0.6%) isolates over 4 yrs

29 Effect of Universal Screening: University of Geneva Hospital [Harbarth et al, JAMA 2008] Prospective interventional cohort with crossover Prospective interventional cohort with crossover 21,754 pts (multiple surgical subspecialty wards) 21,754 pts (multiple surgical subspecialty wards) Rapid screening + standard infection control measures vs. standard measures alone Rapid screening + standard infection control measures vs. standard measures alone MRSA Screening before or on admission by PCR MRSA Screening before or on admission by PCR Standard infection control for MRSA carriers Standard infection control for MRSA carriers –Contact isolation –Gown, mask, gloves –Adjusted perioperative abx –Mupirocin & chlorhexidine x 5 days Universal rapid MRSA admission screening did not reduce nosocomial MRSA infection Universal rapid MRSA admission screening did not reduce nosocomial MRSA infection

30 Incidence of MRSA Infections [Harbarth et al, JAMA 2008]

31 Harbarth et al: Results 94% (10,193/10,844) screened 94% (10,193/10,844) screened –21,754 pts--70% power to detect reduction in MRSA infection rate from 0.9% to 0.6% 5.1% (515 pts) MRSA-positive 5.1% (515 pts) MRSA-positive No difference in MRSA SSI rate No difference in MRSA SSI rate –0.99% (76 pts) without screening –1.14% (93 pts) with screening 57% (53/93 pts) with nosocomial MRSA infection during screening period were MRSA-free on admission 57% (53/93 pts) with nosocomial MRSA infection during screening period were MRSA-free on admission –31% of MRSA carriers identified after surgery –43% of MRSA carriers identified before surgery rec’d appropriate abx prophylaxis

32 Harbarth et al None of MRSA carriers detected during outpatient preop visits developed MRSA infection None of MRSA carriers detected during outpatient preop visits developed MRSA infection –all received decolonization treatment & appropriate antibiotic prophylaxis 57% of infections hospital-acquired 57% of infections hospital-acquired

33 Preoperative Decolonization University of Pittsburgh University of Pittsburgh Prospective observational study Prospective observational study Total joint arthroplasty Total joint arthroplasty 1966 patients 1966 patients –636 screened (nasal) 26% positive for S. aureus (164/636) 26% positive for S. aureus (164/636) 23% MSSA (147/636) 23% MSSA (147/636) 3% MRSA (17/636) 3% MRSA (17/636) –1330 control (not screened) [Rao et al, Clin Orthop Relat Res 2008]

34 Pittsburgh Protocol Decolonization Decolonization –Pts educated 1 wk preop –Mupirocin nasal ointment BID x 5 days –Chlorhexidine bath QD x 5 days

35 Pittsburgh Results

36 No increase in infection from other pathogens No increase in infection from other pathogens Estimated economic gain of $231,741/yr Estimated economic gain of $231,741/yr

37 NEBH Experience: Background FY SSI in 8986 surgical pts (0.5%) –National rate for orthopedic SSI ~ 1.5% 57% SSI due to S. aureus –16 (35%) MSSA –10 (22%) MRSA PFGE of isolates documented community acquired strains

38 February anonymous nares cultures after patient anesthetized Results: 38 – S. aureus (29%) *5 - MRSA ( 4%) all previously undiagnosed *no precautions used in OR, PACU or nursing units *Cefazolin used for antibiotic prophylaxis Anonymous Nasal Surveillance Cultures

39 Screening Proposals February 2006 – prepared three screening proposals with costs 1) Traditional nasal cultures - 3 day results $245, )Purchase rapid PCR equipment $337, )Lease rapid PCR equipment $259, March 2006 –Board approval of equipment purchase

40 March – October 2006 –Weekly meetings: surgical services, infection control, micro, administration, & medical staff members –July 2006 – letter to surgeons –July 17, 2006 – initiated pilot on Spine Service –August 2006 – letter to medical staff –September 2006 – initiated universal program for all inpatient surgery Implementation – 8 Months

41 Policy & Procedure Formalization Protocol developed for all departments & units affected –OR Scheduling –Patient Access –Prescreening Unit –Pre-surgical unit –OR –PACU –Nursing Units –Microbiology Lab –Ancillary Departments: Housekeeping, Central Transport, Radiology, etc.

42 NEBH Program: Preoperative Outpatient Screening Nasal swabs during prescreening Microbiology Laboratory PCR detects presence of bacteria-specific DNA –Cepheid GeneXpert –Results within 24 hrs for S. aureus, 2 hrs for MRSA Topical decolonization protocol for patients found to be carriers of S. aureus or MRSA

43 Topical Decolonization Protocol Intranasal 2% mupirocin ointment (Bactroban) BID x 5 days Shower with 2% chlorhexidine (Hibiclens) daily x 5 days Patients called by PASU to initiate treatment protocol Repeat call to document compliance MRSA carriers re-screened prior to surgery Contact precautions if 2nd MRSA screen positive Vancomycin preop antibiotic prophylaxis for all patients with history of MRSA carrier status

44 Results Study group (7/17/06 to 9/30/07) –7019 patients screened 5122 (73.0%) non-carriers 1588 (22.6%) S. aureus positive 309 ( 4.4%) MRSA positive

45 13/7019 (0.18%) SSI cases in screened patients –7/5122 (0.14%) in noncarriers (0.14%) 1/5122 MRSA(0.02%) 6/5122 S. aureus(0.11%) –6/1897 (0.31%) in carriers 3/309 + MRSA(0.97%) 3/ S. aureus (0.19%) SSI rate higher in carriers, highest in MRSA carriers S. aureus & MRSA SSI Rate

46 Time Period Inpatient surgeries Total SSI SSI Rate FY06 (no screening) 10/01/05-07/16/ * % FY07 (prescreening) 07/17/06-09/30/ ** % *historical controls **study group MRSA & S. Aureus SSI Rates 61% Reduction in S. aureus/MRSA SSI Rate

47 0. 18 % % 0.26% 0.13 % 50% Reduction in MSSA SSI 60% Reduction in MRSA SSI MRSA SSI RateMSSA SSI Rate 10/01/05-07/16/0607/17/06-09/30/0710/01/05-07/16/0607/17/06-09/30/07

48 Study Limitations –Use of historical controls

49 Problem with Historical Controls University of Amsterdam, The Netherlands University of Amsterdam, The Netherlands Prospective double-blind, placebo-controlled Prospective double-blind, placebo-controlled 614 pts 614 pts –Elective ortho surgery with implants (hip, knee, spine) Eradication rate 83.5% mupirocin, 27.8% placebo Eradication rate 83.5% mupirocin, 27.8% placebo No reduction in SSI rate (primary outcome) No reduction in SSI rate (primary outcome) –Rate of endogenous S. aureus infection 5x lower [Kalmeijer et al, Clin Infect Dis 2002]

50 SSI Rate Spontaneous disappearance of deep infections (SSI surveillance effect?) Spontaneous disappearance of deep infections (SSI surveillance effect?) –Implications for use of historical controls [Kalmeijer et al, Clin Infect Dis 2002]

51 NEBH SSI Rates

52 Conclusions: Program for comprehensive prescreening/treatment of S. aureus & MRSA prior to elective surgery is readily established & well-received Program allows early identification of colonized patients, treatment, & adjustment of antibiotic prophylaxis, early isolation & contact precautions for MRSA Associated with significant reduction in infections due to S. aureus & MRSA MRSA colonized patients continue to have higher rate of SSI

53 First year costs ~$400,000 ~$100,000 for 2 full-time positions: Microbiologist & PASU Medical Technician ~$60,000 PCR rapid test equipment ~Lab cost for PCR $40.00/test (compared to routine culture ~ $20.00) ~ 6,000 inpatient surgeries = $240,000 NEBH Program Cost

54 Cost-effectiveness Analyses Compared 3 strategies Compared 3 strategies Screen & treat Screen & treat Treat all Treat all Nothing Nothing –Assumptions S. aureus carrier rate 23.1% S. aureus carrier rate 23.1% Mupirocin efficacy 51%, cost $48.36 Mupirocin efficacy 51%, cost $48.36 Costs: septicemia $25,128, pneumonia $18,366, SSI $16,256 Costs: septicemia $25,128, pneumonia $18,366, SSI $16,256 Both treatment strategies cost-saving Both treatment strategies cost-saving –Treat all: prevents 1 infection/116 pts; 1 death/10,000 pts; save $88/pt –Screen & treat: prevents 1 infection/27 pts; 1 death/2500 pts; save $102/pt [Young and Winston, Infect Control Hosp Epidemiol 2006]

55 Cost-effectiveness Budget impact model of rapid testing & decolonization Budget impact model of rapid testing & decolonization –7,181,484 elective surgeries in US (2003) –Rapid test cost $25/pt sensitivity 52% sensitivity 52% Specificity 85% Specificity 85% –Decolonization cost $72.50/pt 56.5% effective 56.5% effective –7.5% SSI rate 7.5% in carriers 7.5% in carriers 1.5% in noncarriers 1.5% in noncarriers $231,538,400 cost saving, 364,919 fewer hospital days, 935 fewer in-hospital deaths $231,538,400 cost saving, 364,919 fewer hospital days, 935 fewer in-hospital deaths Noskin et al, Infect Control Hosp Epidemiol 2008] [ Noskin et al, Infect Control Hosp Epidemiol 2008]

56 Intangible Benefits NEBH S. aureus/MRSA prescreening & eradication program viewed very favorably as positive pro- active infection control measure by staff, patients, family members & media Allows additional patient education on importance of hand hygiene, prevention of SSI, & infection control measures in home to reduce transmission of MRSA & S. aureus

57 Concerns

58 NEBH Screening Results 7/17/06 to 9/30/07 –7019 patients screened 1588 (22.6%) S. aureus positive 309 ( 4.4%) MRSA positive through April 30, 2008 –10,815 patients screened 2712 ( 25%) S. aureus positive 507 ( 5%) MRSA positive Repeat nasal screens of MRSA carriers reveal 78% eradication rate Prevalence of carriers increasing

59 Time Period Inpatient surgeries Surgical Infections Infec. Rate FY06 10/01/05-07/16/ % FY07 07/17/06-09/30/ % FY08 10/01/07-06/30/ % New England Baptist Hospital MRSA/MSSA Infection Rates

60 Conclusions Targeted active surveillance useful Targeted active surveillance useful –In outbreaks –In high-risk populations, e.g. ICU’s Efficacy of universal surveillance & eradication remains unproven Efficacy of universal surveillance & eradication remains unproven –Depends on regional variations in MRSA/MSSA epidemiology –Depends on hospital surveillance data Stanford vs. UCSF Stanford vs. UCSF

61 Acknowledgements Maureen Spencer, RN Brian Kwon, MD NEBH Board of Trustees Joseph Dionisio, NEBH President and CEO Ling Li, PhD David Hunter, MD, PhD

62 Thank You


Download ppt "MRSA Prescreening and Eradication: New England Baptist Hospital Experience David H. Kim, MD Director of Medical Education New England Baptist Hospital."

Similar presentations


Ads by Google